Correspondence on : 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al
| Errataetall: |
CommentOn: Ann Rheum Dis. 2020 Oct;79(10):1277-1285. - PMID 32620597 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 81(2022), 10 vom: 29. Okt., Seite e196 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheng, Chao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 14.09.2022 Date Revised 07.12.2022 published: Print-Electronic CommentOn: Ann Rheum Dis. 2020 Oct;79(10):1277-1285. - PMID 32620597 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2020-218616 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313905290 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313905290 | ||
| 003 | DE-627 | ||
| 005 | 20231225151600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2020-218616 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM313905290 | ||
| 035 | |a (NLM)32816698 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheng, Chao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correspondence on |b 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.09.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Ann Rheum Dis. 2020 Oct;79(10):1277-1285. - PMID 32620597 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a inflammation | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a sarilumab |2 NLM | |
| 650 | 7 | |a NU90V55F8I |2 NLM | |
| 700 | 1 | |a Zhang, Fangjie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 81(2022), 10 vom: 29. Okt., Seite e196 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2022 |g number:10 |g day:29 |g month:10 |g pages:e196 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2020-218616 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2022 |e 10 |b 29 |c 10 |h e196 | ||